File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Psychotropic Medication Prescribing for Neuropsychiatric Comorbidities in Individuals Diagnosed with Autism Spectrum Disorder (ASD) in the UK

TitlePsychotropic Medication Prescribing for Neuropsychiatric Comorbidities in Individuals Diagnosed with Autism Spectrum Disorder (ASD) in the UK
Authors
KeywordsAutism spectrum disorder
Psychotropic medication
Prevalence
Incidence
Issue Date2020
PublisherSpringer New York LLC. The Journal's web site is located at http://springerlink.metapress.com/openurl.asp?genre=journal&issn=0162-3257
Citation
Journal of Autism and Developmental Disorders, 2020, v. 50, p. 625-633 How to Cite?
AbstractAutism spectrum disorder (ASD) is a lifelong disorder. In the UK, risperidone is the only psychotropic medication approved for the management of the behavioural symptoms that may accompany autism. This is a population-based study aimed to provide an evaluation of the changing trend in the incidence and prevalence of ASD and to analyse the pattern of psychotropic medication prescribing in the UK. 20,194 patients with ASD were identified. The prevalence increased 3.3-fold from 0.109 per 100 persons in 2009 to 0.355 per 100 persons in 2016. Approximately one-third of the identified cohort was prescribed at least one psychotropic medication. Although the medications approved to manage the symptoms of ASD are limited, the prescribing of such medications is increasing. Autism spectrum disorder (ASD) is a persistent neurodevelopmental condition characterised by social communication impairment and stereotyped, repetitive patterns of behaviour (APA 2013). A previous study in the United Kingdom (UK) using electronic primary care data showed that the incidence rate of pervasive developmental disorders (PDDs) increased from 0.40/10,000 (95% CI 0.30–0.54) to 2.98/10,000 (95% CI 2.56–3.47) person-years between 1991 and 2001 (Smeeth et al. 2004b). Another study showed that 70% of 112 children with autism had at least one neuropsychiatric comorbid disorder, of which the most common diagnosis was social anxiety disorder (29.2%; 95% CI 13.2–45.1) (Simonoff et al. 2008). Psychotropic medications, such as antipsychotics, antidepressants, antiepileptic drugs and stimulants, have been used for ASD patients with associated comorbid conditions (National Collaborating Centre for Mental Health 2012). There is, however, limited evidence to guide psychotropic medication prescribing in the ASD population. Risperidone is the only drug approved by the European Medicines Agency (EMA), the Medicines and Healthcare Products Regulatory Agency (MHRA) of the UK, and the Australian Therapeutic Goods Administration (TGA) for the management of behavioural disturbance in children and adolescents with autism and conduct disorder (European Medicines Agency 2007; World Health Organisation 2013). ASD can lead to impairment of the quality of life and the productivity of affected persons and their families; therefore, ASD and its complications have a significant impact on society and the individual, which should not be ignored. The aim of this study was to provide up-to-date information on the prevalence of ASD, psychiatric comorbidities and psychotropic medication prescribing in a UK population sample with individuals from all ages. We also aimed to examine the average duration of psychotropic treatment in treated patients.
Persistent Identifierhttp://hdl.handle.net/10722/284941
ISSN
2023 Impact Factor: 3.2
2023 SCImago Journal Rankings: 1.344
PubMed Central ID
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorAlfageh, BH-
dc.contributor.authorMan, KKC-
dc.contributor.authorBesag, FMC-
dc.contributor.authorAlhawassi, TM-
dc.contributor.authorWong, ICK-
dc.contributor.authorBrauer, R-
dc.date.accessioned2020-08-07T09:04:38Z-
dc.date.available2020-08-07T09:04:38Z-
dc.date.issued2020-
dc.identifier.citationJournal of Autism and Developmental Disorders, 2020, v. 50, p. 625-633-
dc.identifier.issn0162-3257-
dc.identifier.urihttp://hdl.handle.net/10722/284941-
dc.description.abstractAutism spectrum disorder (ASD) is a lifelong disorder. In the UK, risperidone is the only psychotropic medication approved for the management of the behavioural symptoms that may accompany autism. This is a population-based study aimed to provide an evaluation of the changing trend in the incidence and prevalence of ASD and to analyse the pattern of psychotropic medication prescribing in the UK. 20,194 patients with ASD were identified. The prevalence increased 3.3-fold from 0.109 per 100 persons in 2009 to 0.355 per 100 persons in 2016. Approximately one-third of the identified cohort was prescribed at least one psychotropic medication. Although the medications approved to manage the symptoms of ASD are limited, the prescribing of such medications is increasing. Autism spectrum disorder (ASD) is a persistent neurodevelopmental condition characterised by social communication impairment and stereotyped, repetitive patterns of behaviour (APA 2013). A previous study in the United Kingdom (UK) using electronic primary care data showed that the incidence rate of pervasive developmental disorders (PDDs) increased from 0.40/10,000 (95% CI 0.30–0.54) to 2.98/10,000 (95% CI 2.56–3.47) person-years between 1991 and 2001 (Smeeth et al. 2004b). Another study showed that 70% of 112 children with autism had at least one neuropsychiatric comorbid disorder, of which the most common diagnosis was social anxiety disorder (29.2%; 95% CI 13.2–45.1) (Simonoff et al. 2008). Psychotropic medications, such as antipsychotics, antidepressants, antiepileptic drugs and stimulants, have been used for ASD patients with associated comorbid conditions (National Collaborating Centre for Mental Health 2012). There is, however, limited evidence to guide psychotropic medication prescribing in the ASD population. Risperidone is the only drug approved by the European Medicines Agency (EMA), the Medicines and Healthcare Products Regulatory Agency (MHRA) of the UK, and the Australian Therapeutic Goods Administration (TGA) for the management of behavioural disturbance in children and adolescents with autism and conduct disorder (European Medicines Agency 2007; World Health Organisation 2013). ASD can lead to impairment of the quality of life and the productivity of affected persons and their families; therefore, ASD and its complications have a significant impact on society and the individual, which should not be ignored. The aim of this study was to provide up-to-date information on the prevalence of ASD, psychiatric comorbidities and psychotropic medication prescribing in a UK population sample with individuals from all ages. We also aimed to examine the average duration of psychotropic treatment in treated patients.-
dc.languageeng-
dc.publisherSpringer New York LLC. The Journal's web site is located at http://springerlink.metapress.com/openurl.asp?genre=journal&issn=0162-3257-
dc.relation.ispartofJournal of Autism and Developmental Disorders-
dc.rightsThis is a post-peer-review, pre-copyedit version of an article published in [insert journal title]. The final authenticated version is available online at: http://dx.doi.org/10.1007/s10803-019-04291-8-
dc.subjectAutism spectrum disorder-
dc.subjectPsychotropic medication-
dc.subjectPrevalence-
dc.subjectIncidence-
dc.titlePsychotropic Medication Prescribing for Neuropsychiatric Comorbidities in Individuals Diagnosed with Autism Spectrum Disorder (ASD) in the UK-
dc.typeArticle-
dc.identifier.emailMan, KKC: mkckth@hku.hk-
dc.identifier.emailWong, ICK: wongick@hku.hk-
dc.identifier.authorityWong, ICK=rp01480-
dc.description.naturelink_to_OA_fulltext-
dc.identifier.doi10.1007/s10803-019-04291-8-
dc.identifier.pmid31724119-
dc.identifier.pmcidPMC6994549-
dc.identifier.scopuseid_2-s2.0-85075205418-
dc.identifier.hkuros311797-
dc.identifier.volume50-
dc.identifier.spage625-
dc.identifier.epage633-
dc.identifier.isiWOS:000496203600001-
dc.publisher.placeUnited States-
dc.identifier.issnl0162-3257-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats